Capricor (CAPR) news

Capricor Therapeutics shares gain 15.6%

Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares rose 15.6% on September 30, 2026, following a recent earnings report and updated guidance. The company reported a loss of $0.70 per share for the last quarter, which was below the estimated loss of $0.59 per share, representing a 18.87% earnings…

Capricor Therapeutics, Inc.: B. Riley raises to buy from neutral; raises target price to $21 from $5

B. Riley & Co. has upgraded its rating for Capricor Therapeutics, Inc. (CAPR) from "neutral" to "buy," reflecting a more favorable outlook on the company's prospects. Alongside the rating change, the firm has raised its price target for the stock to $21 from $5. The adjustment suggests that B.…

Capricor Therapeutics shares up 5% after Piper Sandler raises to overweight from neutral

Capricor Therapeutics spikes higher, up 33%

Capricor Therapeutics (NASDAQ: CAPR) shares surged 33% on August 24, 2026, following the release of updated clinical trial data for its lead candidate, CAP-1002, in the treatment of Duchenne muscular dystrophy (DMD) [1]. The data, presented at a recent medical conference, showed improved functional…

Capricor Therapeutics announces extension of PDUFA target action date as FDA continues review of DeramioCel BLA

Capricor Therapeutics (NASDAQ: CAPR) has announced that the U.S. Food and Drug Administration (FDA) has agreed to extend the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for deramiocel, an investigational cell therapy for the treatment of…